1 **Biallelic pathogenic variants in TRMT1 disrupt tRNA modification and induce a**

2 **syndromic neurodevelopmental disorder**

3

4 Stephanie Efthymiou^{1,#}, Cailyn P Leo^{2,#}, Chenghong Deng^{2,#}, Kejia Zhang², Sheng-Jia Lin³, Reza 5 Maroofian¹, Rauan Kaiyrzhanov¹, Renee Lin¹, Irem Karagoz¹, Annarita Scardamaglia¹, Daniel 6 Owrang^{4,5}, Valentina Turchetti¹, Friederike Jahnke^{4,5}, Cassidy Petree³, Anna V Derrick⁶, Mark I 7 Rees^{6,7}, Javeria Raza Alvi⁸, Tipu Sultan⁸, Chumei Li⁹, Marie-Line Jacquemont¹⁰, Frederic Tran-8 Mau-Them^{11,12}, Maria Valenzuela-Palafoll¹³, Rich Sidlow¹⁴, Grace Yoon¹⁵, Michelle Morrow¹⁶, 9 Alexis Carere¹⁷, Mary O'Connor¹⁸, Julie Fleischer¹⁷, Erica H Gerkes¹⁸, Chanika Phornphutkul¹⁹, 10 Bertrand Isidor^{20,21}, Clotilde Rivier-Ringenbach²², Christophe Philippe^{11,23}, Semra H Kurul^{24,25,26}, 11 Didem Soydemir²⁴, Bulent Kara²⁷, Deniz Sunnetci-Akkoyunlu²⁸, Viktoria Bothe²⁹, Konrad 12 Platzer²⁹, Dagmar Wieczorek³⁰, Margarete Koch-Hogrebe³¹, Nils Rahner³², Ann-Charlotte 13 Thuresson³³, Hans Matsson³³, Carina Frykholm³³, Sevcan Tuğ Bozdoğan^{34,35}, Atıl Bişgin^{34,35}, 14 Nicolas Chatron^{36,37}, Gaetan Lesca^{36,37}, Sara Cabet^{38,39}, Zeynep Tümer^{40,41}, Tina D Hjortshøj⁴⁰, 15 Gitte Rønde⁴², Thorsten Marquardt⁴³, Janine Reunert⁴³, Erum Afzal⁴⁴, Mina Zamani^{45,46}, Reza 16 Azizimalamiri⁴⁷, Hamid Galehdari⁴⁵, Pardis Nourbakhshd⁴⁸, Niloofar Chamanrou^{45,46}, Seo-17 Kyung Chung^{6, 49,50}, Mohnish Suri⁵¹, Paul J Benke⁵², Maha S Zaki⁵³, Joseph G Gleeson⁵⁴, Daniel 18 G Calame^{55,56,57}, Davut Pehlivan⁵⁷, Halil I Yilmaz⁵⁸, Alper Gezdirici⁵⁸, Aboulfazl Rad⁵⁹, Iman 19 Sabri Abumansour^{60,61,62}, Gabriela Oprea⁵⁹, Jai Sidpra⁴⁶, Kshitij Mankad⁶³, Barbara Vona^{4,5}, 20 Andrew E Fry^{64,65}, Gaurav K Varshney³, Henry Houlden^{1*}, Dragony Fu^{2*} 21 #These authors are equal first authors 22 * Correspondence: h.houlden@ucl.ac.uk (clinical studies and human genetics)

23 * Correspondence: $\frac{dragnyfu}{a}$ rochester.edu (functional /molecular studies)

Affiliations

- 1. Department of Neuromuscular disorders, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
- 2. Department of Biology, Center for RNA Biology, University of Rochester, Rochester, New York, USA.
- 3. Genes & Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
- 4. Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
- 5. Institute of Human Genetics, University Medical Center Göttingen, Heinrich-Düker-Weg 12, 37073, Göttingen, Germany.
- 6. Neurology Research Group, Institute of Life Science, Swansea University Medical School, Swansea University SA2 8PP, UK.
- 7. Faculty of Medicine & Health, Camperdown, University of Sydney, Sydney, Australia.
- 8. Department of Pediatric Neurology, Institute of Child Health, Children's Hospital, Lahore 54590, Pakistan.
- 9. McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada.
- 10. Unité de Génétique Médicale et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU de la Réunion, Saint-Pierre, France.
- 11. Unité Fonctionnelle Innovation en Diagnostic Génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France.
- 12. INSERM UMR1231 GAD, F-21000, Dijon, France.
- 13. Department of Clinical and Molecular Genetics, Vall d´Hebron University Hospital and Medicine Genetics Group, Vall d´Hebron Research Institute, Barcelona, Spain.
- 14. Department of Medical Genetics and Metabolism, Valley Children's Hospital, Madera, California, USA.
- 15. Hospital for Sick Children, Toronto, Canada; University of Toronto, Toronto, Canada.
- 16. GeneDx, Gaithersburg MD USA.
- 17. Department of Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
- 18. Department of medical genetics, University of Groningen, University Medical Center Groningen, Department of Genetics, The Netherlands.
- 19. Division of Human Genetics, Department of Pediatrics, Warren Alpert Medical School of Brown University, Hasbro children's Hospital, RI, USA.
- 20. Centre Hospitalier Universitaire de Nantes, Service de Génétique Médicale, Nantes, France.
- 21. INSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.
- 22. Hôpital Nord-Ouest, Service de Neuropédiatrie, Villefranche sur Saône, France.
- 23. Laboratoire de Génétique, Hôpital Mercy, CHR Metz-Thionville, Metz, France.
- 24. Department of Pediatric Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.
- 25. Izmir Biomedicine and Genome Center, Dokuz Eylül University Health Campus, İzmir, Turkey.
- 26. Izmir International Biomedicine and Genome Institute, Dokuz Eylül University, İzmir, Turkey.
- 27. Division of Pediatric Neurology, Department of Pediatrics, Kocaeli University, Kocaeli,
- Turkey.

- 28. Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
- 29. Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
- 30. Institute of Human Genetics, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
- 31. Vestische Kinder- und Jugendklinik Datteln, Abteilung für Neuropädiatrie, Datteln, Germany.
- 32. MVZ Institute for Clinical Genetics and Tumor Genetics, Bonn, Germany.
- 33. Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala, Uppsala University, 751 85, Uppsala, Sweden.
- 34. Cukurova University AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center), Adana, Turkey.
- 35. Department of Medical Genetics, Cukurova University Faculty of Medicine, Adana, Turkey.
- 36. Hospices Civils de Lyon, Service de Génétique, Centre Labélisé Anomalies du 83 Développement CLAD Sud-Est, Lyon, France.
- 37. Institut Neuromyogène, Laboratoire Physiopathologie et Génétique du Neurone et du Muscle, Equipe Métabolisme énergétique et développement neuronal, CNRS UMR 5310, INSERM U1217, Université Lyon 1, Lyon, France.
- 38. Pediatric, Woman and Fetal Imaging Department, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, 69500 Bron, France.
- 38.
- 39. Institut NeuroMyoGène, CNRS UMR5292, INSERM U1028, Claude Bernard Lyon 1 91 University, 69000 Lyon, France.
- 40. Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
- 41. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- 42. Department of Paediatrics and Adolescent Medicine, University Hospital Herlev, Herlev, Denmark.
- 43. Department of Paediatrics, Metabolic Diseases, University of Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.
- 44. Department of Paediatric Neurology, Children's Hospital and Institute of Child Health, Multan, Punjab 60000, Pakistan.
- 45. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
- 46. Narges Medical Genetics and Prenatal Diagnosis Laboratory, Kianpars, Ahvaz, Iran.
- 47. Department of Pediatric Neurology, Golestan Medical, Educational, and Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- 48. Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- 49. Brain & Mind Centre, Faculty of Medicine & Health, Camperdown, University of Sydney, Sydney, Australia.
- 50. Kids Research, Children's Hospital at Westmead, Sydney, Australia.
- 51. Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK.
- 52. Developmental Biology and Cancer Section, University College London Great Ormond
- Street Institute of Child Health, London, UK, WC1N 1EH.
- 53. Clinical Genetics Department, Human Genetics and Genome Research Division, Centre of Excellence of Human Genetics, National Research Centre, Cairo, Egypt.
- 54. Department of Neuroscience, Rady Children's Institute for Genomic Medicine, University of California, San Diego, San Diego, California, USA.
- 55. Division of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
- 56. Texas Children's Hospital, Houston, TX, USA.
- 57. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
- 58. Department of Medical Genetics, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
- 59. Arcensus GmbH, Rostock, Germany.
- 60. Neurogenetic section, Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
- 61. Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
- 62. Department of Pediatric, International Medical Center, Jeddah, Saudi Arabia.
- 63. Department of Radiology, Great Ormond Street Hospital for Children, London, UK.
- 64. Institute of Medical Genetics, University Hospital of Wales, Cardiff, CF14 4XW, UK.
- 65. Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XW, UK.
-

Abstract

 The post-transcriptional modification of tRNAs plays a key role in tRNA folding and function to ensure proper levels of protein synthesis during growth and development. Pathogenic variants in tRNA modification enzymes have been implicated in diverse human neurodevelopmental and neurological disorders. However, the molecular basis for many of these disorders remains unknown, thereby limiting our understanding and potential treatment of pathologies linked to tRNA modification. Here, we describe an extensive cohort of 31 individuals from 24 unrelated families with bi-allelic variants in the *tRNA methyltransferase 1* (*TRMT1*) gene who present with a syndromic neurodevelopmental disorder universally characterized by intellectual disability in affected patients. Developmental delay, behavioral abnormalities and facial dysmorphisms represent additional core phenotypes of this syndrome. The variants include novel and ultra-rare *TRMT1* variants that segregate with clinical pathology. We found that a subset of variants causes mis-splicing and loss of TRMT1 protein expression. Notably, patient cells with *TRMT1* variants exhibit a deficiency in tRNA modifications catalyzed by TRMT1. Molecular analysis of *TRMT1* variants reveal distinct regions of the TRMT1 protein required for tRNA modification activity and binding, including a TRMT1 subdomain critical for tRNA interaction. Importantly, depletion of TRMT1 in zebrafish is sufficient to induce developmental and behavioral phenotypes that recapitulate those observed in human patients with pathogenic *TRMT1* variants. Altogether, these findings demonstrate that loss of TRMT1-catalyzed tRNA modifications leads to a syndromic form of intellectual disability and elucidate the molecular underpinnings of tRNA modification deficiency caused by pathogenic TRMT1 variants.

Introduction

 Frameshift variants in *TRMT1* have been identified as the cause for certain cases of 182 autosomal-recessive ID through exome sequencing (MRT68, MIM# 618302) (13-16). This was followed by the identification of a single bi-allelic missense variant in *TRMT1* associated with

p.Ser467Leu are semi-conserved (Figure 1D). p.Tyr445Leu*fs**28 was found in two independent

individuals (F12:S1 and F15:S1). Similarly, p.Gln219His*fs**22 was found in two independent

families. Overall, these recurring variants suggest a possible founder effect.

 Among the 31 affected individuals, 14 patients were identified with homozygous variants in TRMT1 and 14 patients contained compound heterozygous variants in *TRMT1*. Nineteen of the individuals were male (61%) and 12 were female (39%). Consanguinity was reported in 13 families (54%). Additionally, 11 of the families had a positive family history for neurological diseases (48%). The median age at last follow-up was 11 years. The ethnic composition of the cohort is diverse, including families of Pakistani, Caucasian, Middle Eastern, European, and Hispanic origin (Table 1).

Patients with bi-allelic TRMT1 variants present with a core set of phenotypic features

 The 31 affected individuals with biallelic TRMT1 variants exhibited a core set of phenotypic features encompassing intellectual disability, global developmental delay, and facial dysmorphism (Figure 2A, summarized in Table 1). Video recordings are available for affected

TRMT1 splice site variants alter splicing patterns

 A subset of *TRMT1* variants are predicted to alter mRNA splicing patterns based upon *in silico* splice site prediction algorithms (Supplementary Table 4). To test the effects of the TRMT1 variants on splicing, we generated mini-gene splicing reporter plasmids cloned from the genomic DNA of a healthy wildtype (WT) donor or affected patients. The splicing reporters were transfected into 293T human embryonic cells and splicing analyzed by RT-PCR, sequencing, and fragment analysis (Supplementary Figure 2, Supplementary Data 1, Supplementary Table 5 and Supplementary Table 6).

 The c.255-1G>T and c.310+5G>C variants are predicted to abolish the splice acceptor and donor sites of exon 3, respectively, while the c.311-1G>A variant is predicted to abolish the splice acceptor site of exon 4. The c.454-1G>C variant is predicted to eliminate the splice acceptor site of exon 5. The c.255-1G>T, c.310+5G>C, c.311-1G>A, and c.454-1G>C variants were tested using a construct containing introns 2 to 5. RT-PCR spanning exons 3 through 5 from cells transfected with the WT construct showed a complex splicing pattern due to alternative splicing that was analyzed through Sanger sequencing and fragment analysis (Figure 3A, Supplementary Data 1). From fragment analysis, a total of 53% of protein coding transcripts in WT include exons 289 3 to 5 that were completely eliminated in assays for the c.255-1G \geq T, c.310+5G \geq C, and c.454- 1G>C variants with an abundance of only 10.6% in sample c.311-1G>A (r.255_641del, p.Cys86Gln*fs**24) (Supplementary Table 5 and Supplementary Table 6).

 The c.1107-1G>A variant was predicted to abolish the splice acceptor site of exon 10 and create a cryptic splice site 1 nucleotide downstream from the native canonical splice site that likely causes a deletion of 1 bp and a frameshift r.1108del p.(Ala370Profs*11). The c.1107-1G>A variant was evaluated using a construct spanning introns 8 to 10. RT-PCR of both WT and the c.1107-

cell lines. TRMT1 has been shown to generate the m2,2G modification at position 26 in human

 present as a minor allele in certain populations and is predicted to be non-pathogenic based upon mutation screenings (18).

truncation variant (1-398) from Family 2 were greatly reduced in their ability to reconstitute

 TRMT1, we found that the TRMT1 truncation variant found in Family 2 exhibited defects in binding RNA (Figure 7B, lane 12). Interestingly, we found that the TRMT1-D231N and Q332R variants exhibited increased copurification of tRNAs compared to wildtype TRMT1 while rRNA copurification was decreased (Figure 7C, compare lane 9 to lanes 10 and 11). These results suggest that the D231N and Q332R variants alter the RNA binding specificity of TRMT1 to prefer interaction with tRNAs versus rRNAs. We found that the TRMT1-R169P missense variant from Family 10 and L465 deletion variant found in Family 3 exhibited reduced binding to tRNAs compared to wildtype TRMT1 (Figure 7D, lanes 8 and 10). The reduced tRNA binding by the TRMT1-R169P could explain its diminished ability to reconstitute m2,2G formation in cells. The TRMT1-S363L minor variant exhibited similar binding to tRNAs compared to wildtype TRMT1. The wildtype tRNA binding of the TRMT1-S363L variant is consistent with the wildtype activity of this variant in reconstitution assays observed above. Altogether, these findings uncover the molecular effects of ID-associated TRMT1 variants on methyltransferase activity and tRNA binding that underlie deficits in m2,2G modification in patient cells. **TRMT1 missense variants reveal distinct functional regions required for TRMT1 activity** To gain insight into the functional effects, we mapped the *TRMT1* variants onto a predicted human TRMT1 structure generated through AlphaFold (19). The hypothesized structure of human TRMT1 was aligned with the solved structure of Trm1 bound to SAM from the archaea *Pyrococcus horshiki* (20). Based upon this structural alignment, human TRMT1 is predicted to fold into two domains coinciding with the SAM‐dependent methyltransferase 455 domain and a C-terminal domain unique to Trm1 enzymes (Figure 8, N-terminal domain in blue,

 C-terminal domain in yellow). The N-terminal domain of TRMT1 forms a putative active site for binding of the SAM methyl donor and a pocket for accommodating the G26 nucleotide that undergoes methylation (Figure 8, red dash circle denotes active site, SAM denoted in green). Notably, the D231N and R323C variants are situated near the predicted G26 pocket (Figure 8, D231N and R323C). As shown above, the D231N and R323C variants are defective in tRNA modification activity but retain similar levels of tRNA binding as wildtype TRMT1. This result is consistent with these variants perturbing G26 substrate positioning in the active site and preventing catalysis without a major effect on overall tRNA recognition and binding. Similar to the R323C and D231N variants, the R169P variant lies nearby the putative G26 binding pocket of TRMT1. However, in contrast to the R323C and D231N variants, the R169P variant is predicted to disrupt the formation of a conserved alpha helix within the active site that is likely to cause broader changes in the N-terminal domain. This drastic alteration in structure is consistent with the R169P variant exhibiting defects in both tRNA modification activity and tRNA binding (Figure 7). The C348R, L465-R466deletion, and S467L variants lie within the C-terminal domain that is unique to the Trm1 enzyme family. The C348R variant resides within the C1 subdomain.

 In *Pyrococcus horshiki* Trm1, the C1 subdomain makes numerous hydrophobic contacts with the N-terminal domain (20). Thus, the C348R variant could alter the folding of the C1 subdomain thereby impacting the N-terminal catalytic domain. The L465R and S467L variants lie within a predicted alpha helix of the C3 subdomain, which faces across from the active site (Figure 8, C3). The C3 subdomain exhibits similarity with subdomains in phenylalanine tRNA synthetase that bind the anticodon region of tRNA-Phe (21). This similarity suggests that the C3 subdomain of TRMT1 could form additional contacts with the tRNA anticodon domain during substrate

 binding. Consistent with this role, we have found that the L465R variant disrupts tRNA binding and reconstitution of tRNA modification activity. Altogether, the TRMT1 missense variants reveal distinct functional activities linked to specific subdomains within the TRMT1 polypeptide.

Depletion of Trmt1 in zebrafish causes developmental and behavioral perturbations

 To investigate the loss of TRMT1 function *in vivo*, we used zebrafish as a model and employed the CRISPR/Cas9 method to generate biallelic mutations using three guide RNAs targeting the functional domain. We analyzed the phenotype in the F0 (founder) generation because our previous data suggest that F0 knockouts recapitulate phenotypes from the stable genetic knockouts (22, 23). RT-qPCR results found significant downregulation of *trmt1* mRNA expression in F0 knockouts (Figure 9A). We then used liquid chromatography-mass spectrometry to measure m2,2G levels in whole larvae or head-only samples from Cas9-injected control and *trmt1* F0 knockout larvae. Consistent with the depletion of Trmt1, the levels of m2,2G modification were reduced in both whole larvae or head-only samples from *trmt1* F0 knockout larvae (Figure 9B). In contrast, no significant difference was detected in the levels of the 1-methyladenosine (m1A) modification, which is another widespread tRNA modification (Figure 9C). We performed morphological phenotyping and found that *trmt1* F0 fish exhibited reduced head, eye, and body sizes (Figure 9D to G). These results indicate that depletion of Trmt1 and reduction in m2,2G modifications is sufficient to induce a general developmental delay in zebrafish.

 Given that many affected individuals with pathogenic *TRMT1* variants exhibit behavioral phenotypes, zebrafish larvae were used to identify distinct swimming patterns in response to light and dark conditions. Therefore, we conducted a behavioral assay by exposing zebrafish

 In this study, we identify and characterize novel variants in *TRMT1* that impact mRNA splicing, protein levels and/or enzymatic activity. Our studies define a core set of phenotypic features universally associated with pathogenic *TRMT1* variants that encompasses intellectual disability, global developmental delay, and facial dysmorphism. While no major intrafamilial phenotypic variability was observed, the present cohort exhibited remarkable interfamilial phenotypic variability characterized by a spectrum of behavioral, morphological, and physiological features. These findings are significant by indicating that TRMT1 is required for a common set of developmental and neurological pathways with further clinical outcomes determined by genetic and environmental factors specific to each family.

 Depletion of Trmt1 and m2,2G modifications in zebrafish results in developmental and behavior phenotypes that resemble certain core features of TRMT1-associated syndromes in human patients. Importantly, these findings demonstrate that TRMT1 homologs play a conserved role in the proper development and function of the central nervous system in vertebrates. The future generation of zebrafish strains that are biallelic for the pathogenic variants discovered here will allow us to further dissect the spectrum of phenotypes in an isogenic background.

 Overall, our findings support a model in which loss of m2,2G modifications due to a decrease in functional TRMT1 protein and/or activity results in downstream perturbations in molecular and cellular processes that cause neurodevelopmental phenotypes. Moreover, we find that the penetrance of the core phenotypic effects can depend on the severity of the variant on TRMT1 function in tRNA modification as well as the specific type of change caused by the TRMT1 variant. For example, we find that TRMT1 variants can induce aberrant splicing, but with distinct outcomes that could differentially impact the functional levels of TRMT1. In addition to loss-of-function splice isoforms, there could be aberrant splice variants that exert dominant negative effects by coding for TRMT1 products that bind tRNA substates without modifying them or exhibit gain-of-function properties. It will also be interesting to determine if any of the splice variants serve regulatory roles that are perturbed by the *TRMT1* variants.

 Since TRMT1 is known to modify numerous tRNA targets, each tRNA could be affected to a different extent by a *TRMT1* variant that could account for the variable phenotypic outcomes. For example, the compound heterozygous S467L/R323C variant appears to more severely impact the modification of mt-tRNA-Ile compared to cytoplasmic tRNA-Met. In addition, the TRMT1 protein variants that affect catalytic activity without impacting tRNA binding could retain RNA chaperone functions that are completely abrogated for other TRMT1 protein variants. Future

families across the world indicates that *TRMT1* should be included in genetic registries as a key

disease gene linked to developmental brain disorders with autosomal recessive Mendelian

inheritance (24).

MATERIAL AND METHODS

Recruitment of research subjects

 The 24 families with bi-allelic *TRMT1* variants were identified using the GeneMatcher platform (25) and data sharing with collaborators. Informed consent for genetic analyses was obtained from all subjects. Clinical details of the cohort were obtained by the follow-up of affected individuals. Seizure description is reported in line with the most recent ILAE guidance (26). Parents and legal guardians of all affected individuals gave their consent for the publication of clinical and genetic information according to the Declaration of Helsinki, and the study was approved by The Research Ethics Committee Institute of Neurology University College London (IoN UCL) (07/Q0512/26) and the local Ethics Committees of each participating center. Consent has been obtained from a subset of families to publish medical photographs and video examinations. Brain magnetic resonance imaging (MRI) scans were obtained from 12 affected

individuals and were reviewed by an experienced team of pediatric neuroradiologists. Cerebellar

Cell culture of primary dermal fibroblasts

 brief, the first construct comprised a 1002 bp region spanning introns 2 to 5, encompassing the 614 c.255-1G \ge T, c.310+5G \ge C, c.311-1G \ge A, and c.454-1G \ge C variants. The second construct involved a 416 bp segment spanning introns 8 to 10 to assay splice effects of the c.1107-1G>A variant. Finally, the third construct covered a 446 bp region spanning intron 10 to exon 12, targeting the c.1194G>A variant. These regions were amplified from genomic DNA obtained from the probands and a healthy control using primers containing specific restriction sites (Supplementary Table 7). The PCR fragments were ligated between exons A and B of the linearized pSPL3-vector following digestion with restriction enzymes. The recombinant vectors were transformed into DH5α competent cells (NEB 5-alpha, New England Biolabs, Frankfurt, Germany), plated and incubated overnight. Following colony PCR with SD6 F (Supplementary Table 7) and the target-specific reverse primer, the wild-type and mutant-containing vector sequences were confirmed by Sanger sequencing and transfected into HEK 293T cells (ATCC, Manassas, VA, USA). 2 µg of the respective pSPL3 vectors was transiently transfected using 6 µL of FuGENE 6 Transfection Reagent (Promega, Walldorf, Germany). An empty vector and transfection negative reactions were included as controls. The transfected cells were harvested 24 hours after transfection. Total RNA was isolated using miRNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA) following the manufacturer's protocols. cDNA was PCR amplified using vector-specific SD6 F and SA2 R primers (Supplementary Table 7). The amplified fragments were visualized on a 1% agarose gel. cDNA amplicons were TA cloned following standard protocols with the pCR2.1 vector kit (ThermoFisher, Darmstadt, Germany) and Sanger sequenced. Fragment analysis was performed for construct 1 with FAM-labelled SD6 F and SA2 R primers using the 3500xL Genetic Analyzer (Thermo Fisher Scientific, Waltham,

 MA, USA). Analysis was performed using GeneMapper Software 5 (Applied Biosystems). Analysis and cataloging of protein-coding versus non-protein coding transcripts and their expression was performed using Ensembl and GTEx Portal. Non-coding transcripts were excluded in calculations to determine the average peak area for construct 1. The percentage of each band was calculated using fragment analysis (Supplementary Figure 2, Supplementary Data 1).

Immunoblotting

 For protein immunoblotting, fibroblast or lymphoblast cells were resuspended in hypotonic lysis buffer for protein extraction as noted previously (17, 35, 36). Cell extracts were boiled at 95°C for 5 minutes followed by fractionation on NuPAGE Bis-Tris polyacrylamide gels (Thermo Scientific). Separated proteins were transferred to Immobilon FL polyvinylidene difluoride (PVDF) membrane (Millipore) for immunoblotting. Membrane was blocked by Odyssey blocking buffer for 1 hour at room temperature followed by immunoblotting with the following antibodies: anti-TRMT1 (sc-373687, Santa Cruz Biotechnology), anti-FLAG epitope tag (L00018; Sigma) and anti-actin (L00003; EMD Millipore). Proteins were detected using a 1:10,000 dilution of fluorescent IRDye 800CW goat anti-mouse IgG (925-32210; Thermofisher).

RNA analysis

 RNA was extracted using TRIzol LS reagent (Invitrogen). For primer extension analysis, 1.5 μg of total RNA was pre-annealed with 5'-32P-labeled oligonucleotide and 5x hybridization buffer (250 mM Tris, pH 8.5, and 300 mM NaCl) in a total volume of 7 μl. The mixture was 658 heated at 95 \degree C for 3 min followed by slow cooling to 42 \degree C. An equal amount of extension mix

- in liquid nitrogen and a 37 °C water bath. NaCl was then added to the extracts at a concentration
- 680 of 0.4 M, incubated on ice for 5 mins, and centrifuged at $14,000 \times g$ for 15 min at 4 °C. After

Ethics Statement and Zebrafish Husbandry

 All experimental animal care was performed in accordance with institutional and NIH guidelines and regulations. Zebrafish (*Danio rerio*) were raised and maintained in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility at the Oklahoma Medical Research Foundation (OMRF) under standard conditions. All experiments were conducted as per protocol (22-76) approved by the Institutional Animal Care Committee (IACUC) of OMRF.

Generation of *trmt1* **F0 knockout zebrafish**

Morphological phenotyping

 To assess morphological phenotypes, zebrafish larvae were randomly selected at 4 dpf for imaging. Larvae were manually positioned in 2% methylcellulose (Sigma, USA) under a stereomicroscope and imaged. Head, eye, and body measurements were obtained directly from scale-calibrated images using ImageJ software (NIH). Head size was determined by measuring the distance from the tip of the snout to the end of the operculum (gill cover). Eye size was measured as the eye diameter, and body size was measured as the length from the tip of the snout to the end of the tail. All bright-field images were captured using a Nikon DS-Fi2 high-definition camera mounted on a Nikon SMZ18 stereomicroscope (Nikon, Japan) with auto-Z-stacking capability.

Behavioral assay

 All behavior tests were performed at room temperature (RT), as previously described (22). In brief, to conduct the LDT test, larvae at 4 dpf were delicately moved into individual wells of a 96-well plate, each containing 150 µL of embryo water. The following day, the plate was placed into a Noldus chamber, and locomotion activity was recorded using the DanioVision system, which runs EthoVision XT software (Noldus Information Technology, Leesburg, VA, USA). Specifically, larvae at 5 dpf were allowed a 30-minute habituation period in the light, followed by alternating 30-minute dark and light periods for two cycles. The locomotion activity of the larvae was measured in terms of distance traveled (in millimeters) per minute. The

 The statistical analysis was conducted using GraphPad Prism. Data are presented as indicated in figure legends. For all analyses, the significance level was set at 0.05. Significance was determined using a two-tailed unpaired Student's *t*-test with Welch's correction for two comparisons, as detailed in the figure legends. *P*-values were represented as follows: not significant (ns) *p* ≥ 0.05, **p* < 0.05, ***p* < 0.01, ****p* < 0.001, and *****p* < 0.0001.

Acknowledgements

 The authors would like to thank the affected individuals and their families for their support of this study. One of the authors of this publication (ZT) is a member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN- ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516]. BV is a member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ERN-ITHACA) [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516].

Funding

Competing interests

- M.M.M and A.C are employees of GeneDx, LLC. R.S. is on the advisory board for Guide
- Genetics and Egetis Pharmaceuticals.

Data availability

- The data that supports the findings of this study are available within the paper and in the
- supplementary material. Whole-exome sequencing data are not publicly available due to privacy
- or ethical restrictions. The novel *TRMT1* variants reported in this manuscript were submitted to
- the LOVD database (https://databases.lovd.nl/shared/genes/TRMT1), with the LOVD variant
- IDs: # 0000944528, # 0000944622, # 0000944624, # 0000944625,
- # 0000944626, # 0000944640, # 0000944641, # 0000944642, # 0000944643, # 0000944646, #
- 800 0000944620, # 0000944621, # 0000944647, # 0000944709, # 0000944708, # 0000944710, #
- 0000944712, # 0000944713, # 0000944714, # 0000944715, # 0000944716, #0000959740,
- #0000959741, #0000959742, #0000959743.
-

Author contributions

- Conceptualization: S.E., A.E.F., R.M., D.F.; Data Curation: S.E., C.D., C.L., K.Z., S.J.L, R.Q.L,
- I.K., D.F.; Formal Analysis: S.E., C.D., C.L., K.Z., R.Q.L, I.K. D.O., J.S., K.M. B.V., D.F.;
- Methodology: S.E., B.V., D.F.; Funding Acquisition: B.V., G.V., H.H., D.F. ; Investigation: all
- authors; Recruitment, Clinical, and Diagnostic Evaluations: R.K., F.J., J.R.A., T.S., C.L., M.J.,
- F.T., M.I.V.P., R.S., G.Y., M.O., J.F., E.H.G., C.P., B.I., C.P., S.H., D.S., V.B., K.P., D.W.,
- M.K., N.R., A.T., H.M., C.F., S.T.B., A.B., N.C., G.L., S.C., Z.T., T.D.H., G.R., T.M., J.R.,
- E.A., M.Z., R.A., H.G., P.N., N.C, M.Z., J.G.G., D.G.C., D. P., A.R., I.S.A., G.O., A.E.F.
- Writing-original draft: S.E., C.D., C.L., K.Z., R.Q.L, I.K., D.O., J.S., K.M., B.V., D.F.; Writing-
- review and editing: all authors.
-

815 Table 1. Clinical Details

817

818 Table 1. (Continued)

819

Table 1. (Continued)

821

822

823

827

828

829
830 Table 1. (Continued)

 831
 832

Table 1. (Continued)

833
834 Table 1. (Continued)

835

837 Table 1. (Continued)

838

Figure 1. Genetic summary of the reported individuals with homozygous *TRMT1* **variants. (A)**

Pedigrees of the 24 families described. Square = male; circle = female; black filled symbol =

affected individual; white symbols = unaffected individuals. Double lines indicate consanguinity.

- **(B)** Coding exons of the *TRMT1* mRNA with variants noted. **(C)** Schematic indicating the domains
- of the TRMT1 protein. The red box represents the mitochondrial targeting signal while the blue box
- indicates the class I *S*-adenosyl-methionine (SAM)-dependent methyltransferase domain. The
- yellow box indicates a C-terminal bipartite nuclear localization signal (NLS) embedded within a
- C₃H₁-type zinc finger motif. Variants reported in this study are represented in red, while previously
- reported variants in black. **(D)** Protein multiple sequence alignment in *TRMT1* orthologues shows
- level of conservation of the identified missense residues (indicated in dotted line boxes).

 Figure 3. *TRMT1* **variants induce splicing defects.** Wild-type (WT) and mutant minigenes were transfected in HEK293T cells and their RNA subjected to RT-PCR. **(A)** RT-PCR for WT and mutant minigenes showed complex splicing patterns. We obtained sequencing validation for all except amplicon 2. The presence of additional bands in the WT is attributed to alternative splicing and was quantified in Supplementary Table 5. The only protein coding transcript expressed in the brain includes exons 3-5 that has been eliminated or reduced due to the four variants. The upper left panel shows the RT-PCR agarose gel with the splicing schematic shown for each band to the right. The variant schematic is shown below. Sanger sequencing results of the RT-PCR showing the correctly spliced WT with the deleterious variant effect, exon skipping, as shown by the presence of only pSPL3 vector. The dotted box represents the short version of exon 5. **(B)** RT-PCR of the c.1107-1G>A results in loss of the native splice acceptor site and cryptic splice activation leading to loss of a G and a frameshift. The left panel shows the RT-879 PCR agarose gel with the splicing schematic shown for each band to the right. Exon 10 with 1 bp deletion is represented with a dotted line corresponding to the position of the single bp deletion. **(C)** RT-PCR of the c.1194G>A variant leads to a frameshift due to exon skipping of exons 11 and 12 leading to a frameshift. Asterisks represent assay artifacts. The left panel shows the RT- PCR gel with the splicing schematic shown to the right. Assay design captured part of exon 12 884 that was correctly spliced in the WT control.

 Figure 4. *TRMT1* **gene variants cause changes in TRMT1 protein levels.** (**A**) Representative immunoblot of the indicated proteins from fibroblast cell lines derived from control (C1) or affected patients. (**B, C**) Quantification of TRMT1 levels relative to the control fibroblast cell line after normalization to actin. N=3. (**D**) Representative immunoblot of TRMT1 and actin from lymphoblast cell lines (LCLs) derived from control wildtype (C2) or affected patients. (**E**) 891 Quantification of TRMT1 levels in LCLs after normalization to actin. N=3. Error bars represent standard deviation from the mean. Statistical analysis was performed using one-way ANOVA.

893 *P \leq 0.05; **P \leq 0.01; ***P \leq 0.001; ****P \leq 0.0001; ns, non-significant, P $>$ 0.05.

895 **Figure 5. Patient cells with biallelic** *TRMT1* **variants exhibit a reduction in m2,2G**

 modifications in tRNAs. (**A, B**) Representative gels of primer extension assays to monitor the presence of m2,2G in tRNA-Met-CAU and mt-tRNA-Ile-GAU from the indicated cell lines. 898 m3C₂₀, 3-methylcytosine; m2,2G₂₆, dimethylguanosine; m1G₉, 1-methylguanosine; $>$, labeled oligonucleotide used for primer extension; *, background signal. (**C through F**) Quantification

900 of m2,2G formation by primer extension for the indicated tRNAs. N=3. Error bars represent 901 standard deviation from the mean. Statistical analysis was performed using one-way ANOVA.

902 For (C) and (D), the means of each column was compared to the Control 1 cell line. For (E) and

903 (F), the means of each column was compared to the Control 2 cell line. $*P < 0.05$; $*P < 0.01$;

904 *** $P \le 0.001$; **** $P \le 0.0001$; ns, non-significant, $P > 0.05$.

906 **Figure 6. TRMT1 variants exhibit defects in reconstitution of tRNA modification activity in**

907 **human cells.** (**A through D**) Representative primer extension gels to monitor the presence of

908 m2,2G in tRNA-Met-CAU and mt-tRNA-Ile-GAU from 293T cell lines transfected with the

909 indicated constructs. m3C₂₀, 3-methylcytosine; m2,2G₂₆, dimethylguanosine; m1G₉, 1-

910 methylguanosine; >, labeled oligonucleotide used for primer extension; *, background signal. (**E,**

911 **F**) Quantification of m2,2G formation by primer extension for the indicated tRNAs. Primer

912 extensions were performed three times and error bars represent the standard error of the mean.

913 Statistical analysis was performed using one-way ANOVA. *P ≤ 0.05 ; **P ≤ 0.01 ; ***P \leq

914 0.001; ****P < 0.0001; ns, non-significant, P > 0.05.

 Figure 7. TRMT1-ID variants perturb the binding of TRMT1 to RNA. (**A, B**) Immunoblot 917 of whole-cell extracts prepared from 293T human embryonic kidney cells transfected with each of the indicated FLAG-tagged constructs. Molecular weight in kilodalton is denoted on the right. (**C, D**) Nucleic acid stain of RNAs extracted from the indicated input or purified samples after denaturing polyacrylamide gel electrophoresis. The migration pattern of tRNAs, 5.8S, and 5S ribosomal RNA is denoted.

Figure 8. Location of missense variants in the predicted structure of human TRMT1. The

methyltransferase domain along with the unstructured N-terminus (gray) are shown while the C-

terminal zinc finger motif has been omitted. The human TRMT1 model was aligned with

Pyrococcus horikoshii Trm1 bound to *S*-adenosyl-methionine (PDB: 2EJT) and domains are

927 colored according to (20). The N-terminal Adenosyl-methionine-dependent methyltransferase

 domain is depicted in blue and C-terminal domain in yellow. Dashed circle represents the putative catalytic active site for binding and methylation of the G26 nucleotide in substrate

tRNAs. *S*-adenosyl-methionine is denoted in green. The locations of TRMT1 variants are noted

in red.

933

934 **Figure 9. Depletion of Trmt1 in zebrafish induces developmental delay and behavioral**

- 935 **abnormalities.** (**A**) RT-qPCR was performed using two sets of primer pairs to examine the 936 expression levels of *trmt1* mRNA in Cas9 control and *trmt1* F0 knockout animals at 4 dpf.
- 937 Experiments were performed with biological and technical triplicates. Expression levels were
- 938 normalized to the *18S* housekeeping gene and compared to the Cas9 animals. Error bar =
- 939 mean ± SD. (**B, C**) LC-MS analysis of m2,2G or m1A in whole larvae or head-only samples. (**D**)
- 940 Representative images for Cas9-injected control (Cas9) and *trmt1* F0 knockouts (F0) at 3 dpf.
- 941 (**E-G**) Quantifications of head, eye, and body sizes for Cas9 and *trmt1* F0 animals. n = 40
- 942 embryos each. The values are presented as a percentage of the mean value of Cas9 controls.
- 943 Error bars = mean ± SD. Each dot represents one larva. (**H**) Locomotor activity analysis, 96-well

- plates containing 96 larvae at 5 dpf were placed in a recording chamber. Larvae were habituated
- in the light for 30 minutes, followed by two 30-minute cycles of alternating dark and light cycles.
- 946 Each point represents the average distance traveled by the animals, with $n = 96$ larvae each. Error
- 947 bars indicate mean \pm SEM. Black arrows indicate the first minute of light cycles. Black bars at
- the bottom indicate the first 10 minutes and green bars indicate the last 20 minutes of dark
- cycles. (**I**) Total distance traveled of each larva in the dark cycles. (**J**) Total distance traveled of
- each larva in the light cycles. (**K**) Total distance traveled of each larva in the last 20 minutes of
- dark cycles. (**L**) Average distance traveled calculated for each larva in the first minute of dark
- 952 cycles. Error bars indicate mean \pm SD. Each dot represents one larva. Mean value of each
- quantification was presented at the bottom of bar. For (B-D, F-I), statistical significance was
- calculated by unpaired *t* test with Welch's correction: **p* < 0.05, ***p* < 0.01, ****p* < 0.001 and
- *****p* < 0.0001.

 14. B. Davarniya *et al.*, The Role of a Novel TRMT1 Gene Mutation and Rare GRM1 Gene Defect in Intellectual Disability in Two Azeri Families. *PLoS One* **10**, e0129631 (2015). 15. D. Monies *et al.*, The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes. *Hum Genet* **136**, 921-939 (2017). 16. H. Najmabadi *et al.*, Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* **478**, 57-63 (2011). 17. K. Zhang *et al.*, An intellectual disability-associated missense variant in TRMT1 impairs tRNA modification and reconstitution of enzymatic activity. *Hum Mutat* **41**, 600-607 (2020). 18. F. J. Martin *et al.*, Ensembl 2023. *Nucleic Acids Res* **51**, D933-D941 (2023). 19. M. Varadi *et al.*, AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res* **50**, D439-D444 (2022). 20. Ihsanawati *et al.*, Crystal structure of tRNA N2,N2-guanosine dimethyltransferase Trm1 from Pyrococcus horikoshii. *J Mol Biol* **383**, 871-884 (2008). 21. L. Mosyak, L. Reshetnikova, Y. Goldgur, M. Delarue, M. G. Safro, Structure of phenylalanyl-tRNA synthetase from Thermus thermophilus. *Nat Struct Biol* **2**, 537-547 (1995). 22. R. Kaiyrzhanov *et al.*, Bi-allelic ACBD6 variants lead to a neurodevelopmental syndrome with progressive and complex movement disorders. *Brain* **147**, 1436-1456 (2024). 23. S. J. Lin *et al.*, Evaluating the association of biallelic OGDHL variants with significant phenotypic heterogeneity. *Genome Med* **15**, 102 (2023). 24. A. J. Gonzalez-Mantilla, A. Moreno-De-Luca, D. H. Ledbetter, C. L. Martin, A Cross- Disorder Method to Identify Novel Candidate Genes for Developmental Brain Disorders. *JAMA Psychiatry* **73**, 275-283 (2016). 25. N. Sobreira, F. Schiettecatte, D. Valle, A. Hamosh, GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat* **36**, 928-930 (2015). 26. R. S. Fisher *et al.*, Instruction manual for the ILAE 2017 operational classification of seizure types. *Epilepsia* **58**, 531-542 (2017). 27. F. Alves, P. Kalinowski, S. Ayton, Accelerated Brain Volume Loss Caused by Anti-beta- Amyloid Drugs: A Systematic Review and Meta-analysis. *Neurology* **100**, e2114-e2124 (2023). 28. C. Garel *et al.*, Biometry of the corpus callosum in children: MR imaging reference data. *AJNR Am J Neuroradiol* **32**, 1436-1443 (2011).

- 29. M. T. Whitehead *et al.*, Refining the Neuroimaging Definition of the Dandy-Walker Phenotype. *AJNR Am J Neuroradiol* **43**, 1488-1493 (2022).
- 30. S. Efthymiou *et al.*, Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination. *Brain* **142**, 2948-2964 (2019).
- 31. S. Richards *et al.*, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **17**, 405-424 (2015).
- 32. J. M. de Sainte Agathe *et al.*, SpliceAI-visual: a free online tool to improve SpliceAI splicing variant interpretation. *Hum Genomics* **17**, 7 (2023).
- 33. S. W. Tompson, T. L. Young, Assaying the Effects of Splice Site Variants by Exon Trapping in a Mammalian Cell Line. *Bio Protoc* **7** (2017).
- 34. A. Rad *et al.*, Aberrant COL11A1 splicing causes prelingual autosomal dominant nonsyndromic hearing loss in the DFNA37 locus. *Hum Mutat* **42**, 25-30 (2021).
- 35. J. Ramos *et al.*, Identification and rescue of a tRNA wobble inosine deficiency causing intellectual disability disorder. *RNA* **26**, 1654-1666 (2020).
- 36. J. M. Lentini, H. S. Alsaif, E. Faqeih, F. S. Alkuraya, D. Fu, DALRD3 encodes a protein mutated in epileptic encephalopathy that targets arginine tRNAs for 3-methylcytosine modification. *Nat Commun* **11**, 2510 (2020).
- 37. R. E. Kingston, C. A. Chen, J. K. Rose, Calcium phosphate transfection. *Curr Protoc Mol Biol* **Chapter 9**, Unit 9 1 (2003).
-